Andy Lin's Long-term Stock Investment Blog

World’s first gene editing therapy Casgevy finally approved

Casgevy, the world’s first gene edit therapy, is an important milestone in the biotech industry and may change the world’s biotech pharmaceutical landscape in the future.

Welcome to leave a message or opinions. But do not have wrong expectations on this site─── we don't tout stocks, no commercials, do not ask whether individual stocks or specific industries are worth buying, individual stock prices, price hints, and stock price predictions; such messages or offenders will be deleted.
The content of this site is the author’s personal opinions and is for reference only. I am not responsible for the correctness, opinions, and immediacy of the content and information of the article. Readers must make their own judgments.
I shall not be liable for any damages or other legal liabilities for any direct or indirect losses caused by readers directly or indirectly relying on and referring to the information on this site, or any liability arising therefrom.
Please do not promote any companies, stocks, or commodities on this site.
Readers can use this link to contact me directly.

error: Content is protected !!